TNFRSF8 and anaplastic large cell lymphoma: Nevertheless, these findings are generally pertinent to patients with the anaplastic large cell lymphoma (ALCL) subtype who accounted for 75% of ECHELON2 population; the extended benefit of this combination to CD30+ beyond ALCL remains therefore uncertain.